查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929638

多价口服轮状病毒疫苗市场（依疫苗类型、剂型、疫苗平台和最终用户划分），全球预测，2026-2032年

Multivalent Oral Rotavirus Vaccine Market by Vaccine Type, Dosage Form, Vaccine Platform, End User Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，多价口服轮状病毒疫苗市场价值将达到 13.9 亿美元，到 2026 年将成长至 15 亿美元，到 2032 年将达到 22.8 亿美元，复合年增长率为 7.33%。

关键市场统计数据
基准年 2025 13.9亿美元
预计年份：2026年 15亿美元
预测年份 2032 22.8亿美元
复合年增长率 (%) 7.33%

多价口服轮状病毒疫苗的策略实施：研发、临床重点、公共卫生重要性与相关人员考量

轮状病毒仍是全球婴幼儿严重肠胃炎的主要原因之一，多价口服疫苗的研发是儿童预防保健领域的重要进展。多价口服轮状病毒疫苗结合了针对多种流行株的抗原覆盖范围，在扩大保护效力的同时，保持了口服给药的便利性，从而确保了常规免疫接种计划的高覆盖率。这种联合接种方案兼顾了免疫学目标与实际操作，尤其适用于注射剂接种在后勤和依从性方面存在挑战的地区。

变革性的产业趋势正在重塑多价口服轮状病毒疫苗的研发、数位化分发、监管路径和公共卫生整合。

随着科学、政策和供应趋势的融合，轮状病毒预防格局正经历一场变革。抗原设计和佐剂策略的创新正在扩大保护范围，而製剂的改进则降低了低温运输的依赖性并简化了给药方式。与这些技术进步相配合的是，政策框架也在不断发展，优先考虑儿童健康综合结果，并强调广谱疫苗组合。

对2025年美国关税调整对疫苗供应经济、采购选择和区域生产策略的影响进行全面分析

美国2025年生效的新关税政策将对多价口服轮状病毒疫苗生态系统产生多方面影响，包括供应链经济、筹资策略和製造地。某些原材料和成品进口关税的提高将增加依赖跨境采购的企业的到岸成本，促使製造商和采购机构重新评估供应商选择、合约条款和总到岸成本的计算。因此，买家和製造商越来越多地考虑在地采购原材料和垂直整合，以降低关税风险。

详细的細項分析表明，疫苗类型、剂型、通路、最终用户环境和年龄组如何决定疫苗的采纳和实施。

细分市场分析揭示了疫苗类型、剂型、通路、终端用户环境和患者人口统计特征等因素如何相互作用，从而影响多价口服轮状病毒疫苗的引进和实施策略。单价疫苗和五价疫苗製剂之间的差异会影响临床定位和采购决策。单价疫苗通常针对安全性已知的特定株，而五价疫苗则强调更广泛的抗原覆盖范围，以应对不同的流行病学情况。这些临床差异会影响后续的选择，例如剂型、供应链设计和宣传讯息。

影响疫苗接种和取得的区域趋势，以及美洲、欧洲、中东和非洲以及亚太地区的差异化实施策略

区域趋势将对多价口服轮状病毒疫苗的研发、部署和持续使用产生重大影响。这反映了法规环境、卫生系统结构和物流能力的差异。在美洲，采购途径通常结合了集中式公共竞标和私部门管道，从而为多种分销模式的共存创造了机会。供应链能力也存在差异，从都市区高度整合的低温运输网络到农村地区产能不足的情况，因此需要製定有针对性的部署策略和健全的上市后监测，以确保疫苗的公平覆盖。

策略性企业行动和竞争策略将科学差异化与製造敏捷性、伙伴关係和分销适应性相结合。

在多价口服轮状病毒疫苗领域，企业层面的策略重点在于产品组合多元化、策略伙伴关係以及生产弹性，以适应临床创新和全球需求波动。主要企业在抗原设计和稳定性方面的内部研发投入与许可和共同开发契约协议之间取得平衡，从而加速地域扩张并加快监管申报进程。与区域製造商和合约开发机构的合作协议有助于扩大生产规模，同时控制资本密集度和营运风险。

为生产者、经销商和政策制定者提供切实可行的、以系统为导向的策略建议，以加速多价口服轮状病毒疫苗的公平推广应用。

产业领导者应采取积极主动、系统性的行动指南，充分利用多价口服轮状病毒疫苗带来的机会，同时应对营运和政策上的挑战。首先，他们应将产品研发重点与专案需求相契合，投资研发兼顾广泛抗原覆盖范围、热稳定性以及目标区域物流能力的製剂。研发工作应辅以真实世界证据项目，以证明疫苗在不同婴幼儿群体中的有效性，从而更有力地推动疫苗纳入国家免疫规划和商业处方集。

严谨的混合调查方法结合了关键相关人员访谈、监管和临床审查、供应链图谱绘製以及情境分析，旨在得出可操作的见解。

本分析的调查方法整合了与关键相关人员的对话、对监管和临床文件的全面审查以及有针对性的供应链分析，以确保获得可靠且可操作的见解。主要研究包括对疫苗研发人员、临床研究人员、监管事务专业人员、采购负责人、医院药房主任和分销合作伙伴进行结构化访谈，以了解不同的营运观点和实际挑战。这些定性见解与临床试验设计文件和监管申报资料相结合，以检验候选疫苗的安全性和有效性。

总之，我们的综合分析强调了将多价疫苗的进步转化为持续的公共卫生影响所需的全面科学、营运和政策努力。

口服多价轮状病毒疫苗的研发路径体现了科学创新、务实配方设计和适应性给药策略的融合，这些因素共同为更全面地保护儿童免受肠道感染疾病提供了一条充满希望​​的途径。进展不仅取决于临床表现，还取决于生产商、经销商和政策制定者能否使产品特性与分销实际情况、监管要求和资金筹措机制相契合。当配方选择和分销模式与当地卫生系统的能力密切匹配时，提高疫苗接种覆盖率和减轻疾病负担的潜力将是巨大的。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 多价口服轮状病毒疫苗市场（依疫苗类型划分）

  • 单价
  • 五价

9. 多价口服轮状病毒疫苗市场（以剂型划分）

  • 冻干粉
  • 口服悬浮液

10. 以疫苗平台分類的多价口服轮状病毒疫苗市场

  • 活病毒疫苗
    • 人类新生儿菌株
    • 人类非新生儿品系
    • 动物-人类重组
  • 失活
    • 所有病毒
    • 部门或次单元
  • 新型口服平台
    • 类病毒颗粒
    • 基于向量
    • 基于RNA的口服给药

第十一章 多价口服轮状病毒疫苗市场（以最终用户类型划分）

  • 公立医疗机构
    • 公立医院
    • 妇幼保健诊所
    • 社区医疗中心
  • 私立医疗机构
    • 私人小儿科诊所
    • 私立医院
    • 多学科诊所
  • 零售及其他设施
    • 零售药局和药局
    • 行动诊所或上门诊所
    • 非政府卫生组织

12. 多价口服轮状病毒疫苗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 多价口服轮状病毒疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国多价口服轮状病毒疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国多价口服轮状病毒疫苗市场

16. 中国多价口服轮状病毒疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bharat Biotech International Limited
  • Bio Farma
  • Biological E. Limited
  • Cadila Healthcare Limited
  • GlaxoSmithKline plc
  • Hilleman Laboratories
  • Indian Immunologicals Limited
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
Product Code: MRR-0A3806951861

The Multivalent Oral Rotavirus Vaccine Market was valued at USD 1.39 billion in 2025 and is projected to grow to USD 1.50 billion in 2026, with a CAGR of 7.33%, reaching USD 2.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.39 billion
Estimated Year [2026] USD 1.50 billion
Forecast Year [2032] USD 2.28 billion
CAGR (%) 7.33%

A strategic introduction to multivalent oral rotavirus vaccine development, clinical priorities, public health relevance, and stakeholder considerations

Rotavirus remains a leading cause of severe gastroenteritis in young children globally, and the development of multivalent oral formulations marks a pivotal evolution in preventive pediatric care. Multivalent oral rotavirus vaccines combine antigenic coverage to target multiple circulating strains, aiming to broaden protective efficacy while preserving the ease of oral administration that supports high uptake in routine immunization schedules. This combination approach aligns immunological objectives with programmatic realities, especially in settings where parenteral delivery poses logistical and adherence challenges.

Recent advances in formulation science, cold-chain management, and clinical trial design have accelerated the translation of multivalent candidates from laboratory to field evaluation. Clinical endpoints now emphasize both symptomatic disease reduction and durable immunogenicity across diverse populations, including infants with varying maternal antibody backgrounds and nutritional statuses. Concurrently, regulatory frameworks have adapted to facilitate robust, comparative assessments that emphasize safety and real-world effectiveness, creating clearer pathways for licensure across geographies.

Stakeholders across the product lifecycle must weigh clinical performance against operational feasibility. Manufacturers are optimizing manufacturing scale and presentation formats to meet heterogeneous procurement channels, while public health authorities consider integration into established vaccination schedules and outreach programs. As supply chain resilience and equitable access emerge as strategic priorities, the multivalent oral rotavirus vaccine portfolio represents not just a scientific advancement but a public health instrument capable of reshaping prevention strategies for enteric disease in early childhood.

Transformative industry shifts reshaping multivalent oral rotavirus vaccine development, distribution digitization, regulatory pathways, and public health integration

The landscape for rotavirus prevention is undergoing transformative shifts driven by converging scientific, policy, and delivery trends. Innovations in antigen design and adjuvant strategies are improving breadth of protection, while formulation work is reducing cold-chain dependence and simplifying administration. These technical advances are matched by evolving policy frameworks that prioritize integrated child health outcomes and increasingly emphasize vaccine portfolios that deliver broad strain coverage.

Simultaneously, digital health and e-commerce channels are reshaping how vaccines and immunization services are coordinated and accessed. Mobile app-based scheduling, electronic immunization registries, and web-based platforms support adherence, real-time surveillance, and efficient supply allocation. The distribution ecosystem is also fragmenting and diversifying; hospital pharmacies, retail pharmacies, and online services each play distinct roles in meeting demand, particularly in markets where private-sector access complements public programs.

Public-private partnerships and collaborative procurement mechanisms are emerging to stabilize supply, incentivize local manufacturing, and align pricing with public health return on investment. In parallel, manufacturers are adopting modular manufacturing and contract-development arrangements to increase agility in responding to demand variability. These combined shifts are redefining value propositions: success increasingly depends on the ability to couple robust clinical performance with operational flexibility, regulatory alignment, and digitally enabled delivery.

Comprehensive analysis of how the United States tariff changes in 2025 reshape supply economics, procurement choices, and regional manufacturing strategies for vaccines

The introduction of new tariff policies in the United States in 2025 has a multifaceted impact on the multivalent oral rotavirus vaccine ecosystem, influencing supply chain economics, procurement strategies, and manufacturing footprints. Increased import duties on certain inputs and finished goods elevate landed costs for organizations that rely on cross-border sourcing, prompting manufacturers and procurement agencies to reassess supplier selection, contract terms, and total landed cost calculations. Buyers and manufacturers consequently intensify scrutiny of input localization and vertical integration to mitigate tariff exposure.

Tariff-driven cost pressures also alter procurement dynamics for public tenders and bilateral supply agreements. Health authorities and program managers confront competing priorities: maintaining affordability for immunization programs while ensuring uninterrupted supply. Some procurement entities may favor suppliers with regional manufacturing capabilities or those able to absorb duties through pricing strategies that preserve program budgets. In response, manufacturers may accelerate capacity investments in tariff-advantaged jurisdictions or explore toll-manufacturing partnerships that allocate value-added activities across borders to optimize duty outcomes.

Beyond direct cost implications, tariff regimes influence strategic decisions about inventory management and risk buffering. Organizations may increase buffer stocks or diversify supplier bases to insulate programs from price volatility and logistic disruptions. Over time, persistent tariff differentials can also catalyze local manufacturing incentives, drawing investment into technology transfer initiatives and partnering with regional contract manufacturers to secure supply resilience and sustain immunization coverage goals.

In-depth segmentation insights showing how vaccine type, dosage presentation, distribution channels, end-user settings, and age cohorts determine adoption and implementation

Segmentation insights reveal the nuanced ways in which vaccine type, dosage form, distribution pathway, end-user setting, and patient age group interact to shape adoption and implementation strategies for multivalent oral rotavirus vaccines. Vaccine type distinctions between monovalent and pentavalent formulations influence clinical positioning and procurement decisions; monovalent options are often positioned for targeted strain coverage with a familiar safety profile, whereas pentavalent candidates emphasize expanded antigenic breadth to address heterogeneous epidemiology. These clinical differentials drive downstream choices in presentation, supply chain design, and advocacy messaging.

Dosage form is pivotal for programmatic fit, with liquid oral suspensions offering ease of administration and compatibility with mass immunization drives, while lyophilized powder presentations provide advantages in thermostability and extended shelf life when reconstitution protocols are operationally feasible. Distribution channels further determine access dynamics: hospital pharmacies serve inpatient and perioperative vaccination needs, online pharmacies accessed via mobile app based platforms or web based platforms extend reach to digitally connected caregivers, and retail pharmacies operating as chain pharmacy networks or independent pharmacy outlets provide community-level accessibility and convenience. Each channel requires tailored cold-chain logistics, inventory management practices, and regulatory compliance measures.

End user segmentation clarifies implementation touchpoints. Hospitals, differentiated into private hospitals and public hospitals, anchor complex care and catch-up immunization programs, while pediatric clinics, including group practice and solo practice models, serve as the frontline for routine infant vaccination and caregiver education. Public health programs provide population-level coverage through national schedules and outreach campaigns, often prioritizing high-risk age windows. Age group stratification into under six months, six to twelve months, and over twelve months informs dosing schedules, catch-up policy design, and communication strategies to maximize on-time uptake. Together, these segmentation layers guide product development decisions, distribution investments, and targeted stakeholder engagement to optimize vaccination outcomes across diverse operational contexts.

Regional dynamics and differentiated implementation strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape vaccine introduction and access

Regional dynamics materially influence how multivalent oral rotavirus vaccines are developed, deployed, and sustained, reflecting differences in regulatory environments, health system structures, and logistical capacities. In the Americas, procurement pathways often blend centralized public tenders with private-sector channels, creating opportunities for multiple distribution models to coexist. Supply chain capabilities range from highly integrated cold-chain networks in urban centers to capacity gaps in rural areas, which necessitate targeted deployment strategies and robust post-marketing surveillance to ensure equitable coverage.

Europe, Middle East & Africa presents a complex mosaic where regulatory rigor, health financing frameworks, and programmatic priorities vary widely across jurisdictions. Some countries emphasize centralized reimbursement and stringent approval pathways, while others prioritize rapid scale-up through global partnerships and public health procurement initiatives. Climatic diversity and infrastructure heterogeneity in this region amplify the value of thermostable formulations and flexible dosing presentations that can adapt to variable storage conditions and outreach modalities.

Asia-Pacific is characterized by high manufacturing capacity and active local production ecosystems, alongside diverse delivery platforms spanning dense urban markets and remote, underserved populations. National immunization programs in several countries coordinate large-scale rollouts supported by digital registries and community health networks, creating fertile ground for integrating multivalent presentations into routine schedules. Across all regions, tailored engagement with regulatory authorities, investment in cold-chain resilience, and alignment with local distribution channels remain central to successful introduction and sustained uptake.

Strategic company behaviors and competitive approaches that couple scientific differentiation with manufacturing agility, partnerships, and distribution adaptability

Company-level strategies in the multivalent oral rotavirus vaccine arena center on portfolio diversification, strategic partnerships, and manufacturing agility to align clinical innovation with global demand variability. Leading developers are balancing internal R&D investments in antigen design and stability with licensing and co-development arrangements that accelerate geographical reach and regulatory filing timelines. Collaborative agreements with regional manufacturers and contract development organizations facilitate scale-up while managing capital intensity and operational risk.

Commercial strategies increasingly prioritize adaptable product presentations to meet distinct procurement preferences and logistical realities. Firms that invest in both liquid oral suspension and lyophilized powder formats position themselves to serve a broader range of markets, from urban clinics to remote outreach programs. In parallel, companies are strengthening distribution networks through partnerships with wholesalers, hospital systems, and digital pharmacy platforms to ensure dependable last-mile delivery and to support adherence-enhancing services such as appointment reminders and cold-chain traceability.

Clinical development pathways emphasize rigorous safety monitoring and post-authorization evidence generation to support both national immunization program inclusion and private market uptake. Firms that transparently share real-world effectiveness data, engage with public health stakeholders, and offer flexible contracting terms are better positioned to secure placement in public tenders and private formularies. Ultimately, the most successful companies will be those that integrate scientific differentiation with pragmatic commercial models and demonstrate commitment to capacity building in regions where sustained supply is mission-critical.

Actionable and system-focused strategic recommendations for manufacturers, distributors, and policymakers to accelerate equitable adoption of multivalent oral rotavirus vaccines

Industry leaders should adopt a proactive, systems-oriented playbook to capitalize on multivalent oral rotavirus vaccine opportunities while addressing operational and policy headwinds. First, align product development priorities with programmatic needs by investing in formulations that balance broad antigenic coverage with thermostability to match the logistical capacities of target geographies. Complement R&D with real-world evidence programs that demonstrate effectiveness across diverse infant populations, thereby strengthening the case for inclusion in national immunization schedules and private formularies.

Second, mitigate tariff and supply-chain exposure through geographic diversification of manufacturing and strategic partnerships with contract manufacturers in tariff-advantaged or high-demand regions. Establish dual-sourcing strategies for critical raw materials and implement robust inventory risk-management frameworks to reduce the likelihood of stockouts during procurement cycles. Third, integrate digital tools across distribution channels to enhance forecasting, traceability, and caregiver engagement; mobile app based platforms and web based platforms can extend reach and improve adherence through automated reminders and electronic recordkeeping.

Fourth, tailor market entry and commercialization strategies to end-user contexts by developing clinic-friendly presentations for pediatric practices and hospital-centric bundles for institutional procurement. Engage proactively with health authorities to design phased introduction plans that include training for cold-chain management and immunization tracking. Finally, adopt transparent pricing and flexible contracting approaches that align manufacturer incentives with public health objectives, enabling sustainable program financing and long-term uptake.

Rigorous mixed-methods research approach combining primary stakeholder interviews, regulatory and clinical review, supply-chain mapping, and scenario analysis to produce actionable insights

The research methodology for this analysis integrates primary stakeholder engagement, comprehensive review of regulatory and clinical documentation, and targeted supply-chain mapping to ensure robust, actionable findings. Primary research included structured interviews with vaccine developers, clinical investigators, regulatory affairs experts, procurement officers, hospital pharmacy directors, and distribution partners to capture diverse operational perspectives and real-world challenges. These qualitative inputs were synthesized with clinical trial design documentation and regulatory filings to validate safety and efficacy considerations across candidate profiles.

Secondary research encompassed examination of peer-reviewed clinical literature, publicly available regulatory guidance, and country-level immunization policies to contextualize programmatic implications and comparative product positioning. Supply-chain analysis used logistics data and stakeholder interviews to map cold-chain capacity, last-mile constraints, and distributor capabilities across representative geographies. Scenario analysis techniques assessed the implications of tariff changes, manufacturing localization, and distribution channel evolution, enabling the identification of strategic levers and mitigation pathways.

Data triangulation and expert review cycles were employed to test assumptions, resolve discrepancies, and ensure the credibility of insights. Limitations of the methodology include variability in publicly available clinical endpoints across candidates and the evolving nature of policy responses to tariff adjustments; these were addressed through sensitivity analyses and by prioritizing direct stakeholder testimony where possible.

Concluding synthesis emphasizing the integrated scientific, operational, and policy actions required to translate multivalent vaccine advances into durable public health impact

The trajectory for multivalent oral rotavirus vaccines reflects a convergence of scientific innovation, pragmatic formulation engineering, and adaptive delivery strategies that together offer a promising route to more comprehensive protection against pediatric enteric disease. Progress hinges not only on clinical performance but on the ability of manufacturers, distributors, and policy makers to synchronize product attributes with distribution realities, regulatory expectations, and financing mechanisms. Where formulation choices and distribution models are thoughtfully aligned with local health system capacities, the potential to improve vaccination coverage and reduce disease burden is substantial.

Decision-makers must therefore take an integrative approach that combines evidence generation, supply-chain resilience, and stakeholder collaboration. By prioritizing thermostable presentations where cold-chain limitations exist, leveraging digital channels to enhance adherence, and pursuing regional manufacturing partnerships to navigate tariff complexities, stakeholders can strengthen the reliability and reach of immunization programs. In sum, the future success of multivalent oral rotavirus vaccines will be determined by strategic coordination across scientific, commercial, and public health domains, ensuring that technical gains translate into measurable improvements in child health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multivalent Oral Rotavirus Vaccine Market, by Vaccine Type

  • 8.1. Monovalent
  • 8.2. Pentavalent

9. Multivalent Oral Rotavirus Vaccine Market, by Dosage Form

  • 9.1. Lyophilized Powder
  • 9.2. Liquid Oral Suspension

10. Multivalent Oral Rotavirus Vaccine Market, by Vaccine Platform

  • 10.1. Live Attenuated
    • 10.1.1. Human Neonatal Strain
    • 10.1.2. Human Non-Neonatal Strain
    • 10.1.3. Animal-Human Reassortant
  • 10.2. Inactivated
    • 10.2.1. Whole Virus
    • 10.2.2. Split Or Subunit
  • 10.3. Novel Oral Platforms
    • 10.3.1. Virus Like Particle
    • 10.3.2. Vector Based
    • 10.3.3. RNA Based Oral Delivery

11. Multivalent Oral Rotavirus Vaccine Market, by End User Type

  • 11.1. Public Health Facilities
    • 11.1.1. Public Hospitals
    • 11.1.2. Maternal And Child Health Clinics
    • 11.1.3. Community Health Centers
  • 11.2. Private Healthcare Providers
    • 11.2.1. Private Pediatric Clinics
    • 11.2.2. Private Hospitals
    • 11.2.3. Multi-Specialty Clinics
  • 11.3. Retail And Alternative Settings
    • 11.3.1. Retail Pharmacies And Drugstores
    • 11.3.2. Mobile Or Outreach Clinics
    • 11.3.3. Non-Governmental Health Organizations

12. Multivalent Oral Rotavirus Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multivalent Oral Rotavirus Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multivalent Oral Rotavirus Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multivalent Oral Rotavirus Vaccine Market

16. China Multivalent Oral Rotavirus Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bharat Biotech International Limited
  • 17.6. Bio Farma
  • 17.7. Biological E. Limited
  • 17.8. Cadila Healthcare Limited
  • 17.9. GlaxoSmithKline plc
  • 17.10. Hilleman Laboratories
  • 17.11. Indian Immunologicals Limited
  • 17.12. Lanzhou Institute of Biological Products Co., Ltd.
  • 17.13. Merck & Co., Inc.
  • 17.14. Panacea Biotec Ltd.
  • 17.15. Pfizer Inc.
  • 17.16. Sanofi S.A.
  • 17.17. Serum Institute of India Pvt. Ltd.
  • 17.18. Shantha Biotechnics
  • 17.19. Sinovac Biotech Ltd.
  • 17.20. Takeda Pharmaceutical Company Limited
  • 17.21. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MONOVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PENTAVALENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIQUID ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NEONATAL STRAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY HUMAN NON-NEONATAL STRAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY ANIMAL-HUMAN REASSORTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SPLIT OR SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VIRUS LIKE PARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VECTOR BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RNA BASED ORAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MATERNAL AND CHILD HEALTH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE PEDIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MULTI-SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES AND DRUGSTORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY MOBILE OR OUTREACH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NON-GOVERNMENTAL HEALTH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY VACCINE PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY NOVEL ORAL PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH FACILITIES, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY PRIVATE HEALTHCARE PROVIDERS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MULTIVALENT ORAL ROTAVIRUS VACCINE MARKET SIZE, BY RETAIL AND ALTERNATIVE SETTINGS, 2018-2032 (USD MILLION)